1. Scrip
  2. >>Therapy Areas

AZ Clears Out Three Respiratory Drugs With Sale To Covis

 
• By Kevin Grogan

The drug giant's strategy of divesting old assets continues apace with the $350m sale of the ciclesonide-based drugs Alvesco, Omnaris and Zetonna to the Swiss specialty pharma group.

Boxes
AZ dusts off more non-core assets to sell • Source: Shutterstock

AstraZeneca PLC is continuing to clean out its non-core asset cupboard and is selling three respiratory drugs for $350m to Switzerland's Covis Pharma BV.

The drug major is selling off the non-US rights (but also US royalties) to Alvesco, an inhaled form of the corticosteroid ciclesonide for persistent asthma, plus Omnaris and Zetonna, which have the same active ingredient as the latter but are sprays used for the treatment of nasal symptoms associated with rhinitis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

More from Therapy Areas

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.